Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04113551 · ClinicalTrials.gov registry record
A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 17,418
- Enrollment target
NCT04113551: Completed study, sponsored by Janssen Research & Development.
NCT04113551 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 17,418 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04113551 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 17,418 participants
- Enrollment target
Study Summary
The purpose of this study is to document the extent of on-label and off-label use of Methylphenidate (MPH) (Concerta), MPH (Ritalin), Atomoxetine (ATO), and Guanfacine (GFC) in Japan.
Primary Outcome
The percentage of participants stratified on age, sex, and medication (Methylphenidate \[MPH\] \[Concerta\], MPH \[Ritalin\], Atomoxetine \[ATO\], Guanfacine \[GFC\]) will be reported. The data will be taken from Japan Medical Data Center (JMDC) database for analysis.
Interventions
- DRUG MPH (Concerta)
- DRUG MPH (Ritalin)
- DRUG Atomoxetine (ATO)
- DRUG Guanfacine (GFC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,418 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2020-01-10 |
What the finished NCT04113551 record still lists
NCT04113551 is an observational study that tracks outcomes without assigning an intervention. Its 17,418 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 4 interventions - of which MPH (Concerta) is the first listed.
NCT04113551 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04113551 about?
NCT04113551 is a clinical study titled "A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan". The purpose of this study is to document the extent of on-label and off-label use of Methylphenidate (MPH) (Concerta), MPH (Ritalin), Atomoxetine (ATO), and Guanfacine (GFC) in Japan.
What is the current status of trial NCT04113551?
This trial is currently completed. The enrollment target is 17,418 participants. The study started on 2019-10-01. Estimated completion is 2020-01-10.
What interventions are being tested in trial NCT04113551?
The interventions under investigation include: MPH (Concerta) (DRUG), MPH (Ritalin) (DRUG), Atomoxetine (ATO) (DRUG), Guanfacine (GFC) (DRUG).
Who is sponsoring clinical trial NCT04113551?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06272110 · 17,500 participants
Promoting Equitable Access to Language Services in Health and Human Services
- NCT07290361 · 17,587 participants · NA
Stratified Targeted Engagement From Primary Care to Physical Therapy (STEPPT)
- NCT06245187 · 17,198 participants
Get With the Guidelines Atrial Fibrillation Registry
- NCT07108660 · 17,800 participants · NA
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI